Brazil approves obesity drug banned in US, Europe

Brazil on Tuesday approved the use of an anti-obesity medication, sibutramine, which has been banned in Europe and the United States, officials said.

The National Health Surveillance Agency (Anvisa) said it would halt sales of weight-loss medications which are based on , but allow sibutramine under heightened surveillance.

The drug will be allowed to be prescribed to patients seeking to lose weight but only if they do not have , Anvisa director Dirceu Barbano told the state news agency Agencia Brasil.

But one Anvisa board member, former Agenor Alvares, dissented.

"If a number of countries took this off the market based on scientific evidence, we cannot ignore that evidence," Alvares said.

According to Agencia Brasil, regulators in February proposed the withdrawal of sibutramine, following the lead of Europe and the United States.

The drug, sold in the United States under the name Meridia, was withdrawn in October 2010 after the European Medicines Agency suspended authorization for all anti-obesity medicines containing sibutramine in January that year amid concerns over the cardiovascular risks.

Barbano said however the evidence showed it is possible to use the medication to lose weight and that health risks can be minimized.

add to favorites email to friend print save as pdf

Related Stories

Genes influence effectiveness of weight-loss drug

Oct 01, 2008

Obese patients with a specific genetic make-up lose more weight when taking the weight loss drug sibutramine and undergoing behavioral therapy compared to those without this genetic make-up, reports a new study in Gastroenterology, the of ...

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FDA scrutinizes weight loss pill from Orexigen

Dec 03, 2010

(AP) -- Scientists for the Food and Drug Administration said Friday a pill to treat obesity from Orexigen Therapeutics Inc. helped patients lose weight, though it didn't meet all the criteria set forth by the agency.

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.